VREX vs. PHAR, ABUS, INNV, EYPT, MD, FNA, ORIC, PETQ, SVRA, and EXAI
Should you be buying Varex Imaging stock or one of its competitors? The main competitors of Varex Imaging include Pharming Group (PHAR), Arbutus Biopharma (ABUS), InnovAge (INNV), EyePoint Pharmaceuticals (EYPT), Pediatrix Medical Group (MD), Paragon 28 (FNA), ORIC Pharmaceuticals (ORIC), PetIQ (PETQ), Savara (SVRA), and Exscientia (EXAI). These companies are all part of the "medical" sector.
Pharming Group (NASDAQ:PHAR) and Varex Imaging (NASDAQ:VREX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
Varex Imaging has a net margin of 4.90% compared to Varex Imaging's net margin of -4.01%. Pharming Group's return on equity of 8.26% beat Varex Imaging's return on equity.
Pharming Group currently has a consensus price target of $37.00, suggesting a potential upside of 308.84%. Varex Imaging has a consensus price target of $27.00, suggesting a potential upside of 83.92%. Given Varex Imaging's higher possible upside, equities analysts clearly believe Pharming Group is more favorable than Varex Imaging.
0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 5.2% of Varex Imaging shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pharming Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Varex Imaging has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Varex Imaging has higher revenue and earnings than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than Varex Imaging, indicating that it is currently the more affordable of the two stocks.
Varex Imaging received 220 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 63.46% of users gave Varex Imaging an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
In the previous week, Pharming Group had 4 more articles in the media than Varex Imaging. MarketBeat recorded 5 mentions for Pharming Group and 1 mentions for Varex Imaging. Pharming Group's average media sentiment score of 1.87 beat Varex Imaging's score of 0.69 indicating that Varex Imaging is being referred to more favorably in the news media.
Summary
Varex Imaging beats Pharming Group on 12 of the 16 factors compared between the two stocks.
Get Varex Imaging News Delivered to You Automatically
Sign up to receive the latest news and ratings for VREX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VREX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Varex Imaging Competitors List
Related Companies and Tools
